Spruce Biosciences Inc (SPRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$57.93+0.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SPRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -52.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SPRB — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Why it matters: Earnings results will show financial health and progress. This affects how investors feel.
Watch forEarnings results show better financial metrics than Q1.
Also watch forEarnings results show more losses or cash burn than expected.
Why it matters: The BLA submission is a key step toward getting TA-ERT approved. Approval could lead to a commercial launch and revenue generation.
Supportive ifThe BLA for TA-ERT is due by December 2026.
Worry ifBLA submission is delayed beyond Q4 2026.
Why it matters: If health care sector growth picks up, it could benefit Spruce. It may signal a better environment for all companies in the space.
Supportive ifHealth care sector revenue growth accelerates back toward its highs.
Worry ifSector revenue growth is slowing down. This shows there are still challenges ahead.
Why it matters: Keeping enough cash is important for funding operations. It helps launch TA-ERT.
Supportive ifCash and cash equivalents remain above $90 million at the end of 2026.
Worry ifCash and cash equivalents fall below $70 million by the end of 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$256 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $984 loss on $10,000 · 9.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,730 loss on $10,000 · 77.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The cash position is crucial for funding operations and supporting the BLA submission. Strong cash flow indicates financial health.
Supportive ifA report will show cash and cash equivalents over $96.3 million after the offering.
Worry ifCash and cash equivalents fall below $96.3 million without a clear funding plan.
Why it matters: Keeping a strong cash position is important. It helps fund operations and support the BLA submission.
Worry ifCash and cash equivalents remain above $90 million through Q4 2026.
Less concerning ifCash and cash equivalents drop below $80 million before Q4 2026.
Why it matters: This investment aims to broaden patient access to TA-ERT. It could enhance the drug's market potential if approved.
Supportive ifThe Expanded Access Program for TA-ERT will launch in Q4 2026.
Worry ifThe Expanded Access Program does not launch as planned in Q4 2026.
Why it matters: Starting this study is crucial for potential FDA accelerated approval of TA-ERT. It shows commitment to advancing the drug.
Supportive ifThe TrAnsform study will start as planned in Q4 2026.
Worry ifThe study does not start in Q4 2026 as anticipated.